Download PDF
Dtsch Med Wochenschr 2002; 127(16): 859-865
DOI: 10.1055/s-2002-25188
Übersichten
© Georg Thieme Verlag Stuttgart · New York

Stellenwert niedermolekularer Heparine in der Therapie akuter koronarer Syndrome

Low-molecular heparins in the treatment of the acute coronary syndromeJ. Carlsson, U. Tebbe
  • 1Medizinische Klinik II (Chefarzt: Prof. Dr. Ulrich Tebbe), Klinikum Lippe, Detmold
Further Information

Publication History

10.12.2001

14.3.2002

Publication Date:
18 April 2002 (online)

Also available at
    Permissions and Reprints

Die Therapie akuter koronarer Syndrome - instabile Angina pectoris und akuter Herzinfarkt - hat sich in den letzten Jahren durch aktuelle Studienergebnisse verändert. Diese Veränderungen beruhen zum einen auf pharmakologischen Neuerungen wie der Plättcheninhibitortherapie mit Clopidogrel und Glykoprotein IIb/IIIa-Antagonisten. Zum anderen hat die Troponinbestimmung zu einer besseren Risikostratifizierung des Patienten mit akutem koronaren Syndrom geführt, so dass Entscheidungen über ein frühes invasives oder konservatives Vorgehen in der Akutsituation möglich sind. Während sich die direkten Thrombininhibitoren in dieser klinischen Situation nicht haben etablieren können, kommt der antithrombotischen Therapie mit niedermolekularen Heparinen (LMWH) als Ersatz für das seit Jahrzehnten verwendete unfraktionierte Heparin (UFH) große Bedeutung zu. Im Folgenden wird der Stellenwert der LMWH in der Therapie akuter koronarer Syndrome vor dem Hintergrund aktueller Studienergebnisse dargestellt.

Literatur

  • 1 Antman E M. Dose-ranging trial of enoxaparin for unstable angina: results of TIMI 11A.  J Am Coll Cardiol. 1997;  29 1474-1482
    Google Scholar
  • 2 Antman E M, Cohen M, Radley D. et al. for the TIMI 11B (Thrombolysis in Myocardial Infarction) and ESSENCE (Efficacy and Safety of Subcutaneous Enoxaparin in Non-Q-wave Coronary Events) Investigators . Assessment of the treatment effect of enoxaparin for unstable angina/non-Q-wave myocardial infarction.  Circulation. 1999;  100 1602-1608
    Google Scholar
  • 3 Antman E M, McCabe C H, Gurfinkel E P. et al. for the TIMI 11B Investigators . Enoxaparin prevents death and cardiac ischemic events in unstable angina/non-Q-wave myocardial infarction. Results of Thrombolysis in Myocardial Infarction (TIMI) 11B Trial.  Circulation. 1999;  100 1593-1601
    Google Scholar
  • 4 Antman E M. The search for replacements for unfractionated heparin.  Circulation. 2001;  103 2310-2314
    Google Scholar
  • 5 The Assessment of the safety and efficacy of a new thrombolytic regimen (ASSENT)-3 investigators . Efficacy and safety of tenecteplase in combination with enoxaparin, abciximab, or unfractionated heparin: the ASSENT-3 randomised trial in acute myocardial infarction.  Lancet. 2001;  358 605-613
    Google Scholar
  • 6 Becker R C, Ball S P, Eisenberg P. et al . A randomized, multicenter trial of weight-adjusted intravenous heparin dose titration and point-of-care coagulation monitoring in hospitalized patients with active thromboembolic disease. Antithrombotic therapy consortium investigators.  Am Heart J. 1999;  137 59-71
    Google Scholar
  • 7 Bertrand M E, Simoons M L, Fox K AA. et al . Management of acute coronary syndromes: acute coronary syndromes without persistent ST segment elevation.  Eur Heart J. 2000;  21 1406-1432
    Google Scholar
  • 8 Braunwald E. Management of unstable angina based on considerations of aetiology.  Heart. 1999;  82 (Suppl I) 15-17
    Google Scholar
  • 9 Braunwald E, Antman E M, Beasley J W. et al . ACC/AHA Guidelines for the management of patients with unstable angina and non-ST-segment elevation myocardial infarction: executive summary and recommendations.  Circulation. 2000;  102 1193-1209
    Google Scholar
  • 10 Carlsson J, Miketic S, Tebbe U. Heparin und niedermolekulare Heparine in der Therapie akuter koronarer Syndrome. München, Medikon Verlag In: Schrader, J. (Hrsg.) Niedermolekulare Heparine - Fragmin. 1. Auflage 1995: 70-81
    Google Scholar
  • 11 Cohen M, Demers C, Gurfinkel E P. et al. for the Efficacy and Safeety of Subcutaneous Enoxaparin in Non-q-wave Coronary Events Study Group (ESSENCE) . A comparison of low-molecular-weight heparin with unfractionated heparin for unstable coronary artery disease.  N Engl J Med. 1997;  337 447-452
    Google Scholar
  • 12 Cohen M, Stinnett S S, Weatherley B D. et al . Predictors of recurrent ischemic events and death in unstable coronary artery disease after treatment with combination antithrombotic therapy.  Am Heart J. 2000;  139 962-970
    Google Scholar
  • 13 Collet J P, Montalescot G, Lison L. et al . Percutaneous coronary intervention after subcutaneous enoxaparin pretreatment in patients with unstable angina pectoris.  Circulation. 2001;  103 658-663
    Google Scholar
  • 14 Collignon F, Frydman A, Caplain H. et al . Comparison of the pharmacokinetic profiles of three low molecular mass heparins - dalteparin, enoxaparin, and nadroparin - administered subcutaneously in healthy volunteers (doses for prevention of thromboembolism).  Thromb Haemost. 1995;  73 630-640
    Google Scholar
  • 15 Eikelbloom I W, Anand S S, Malmberg K, Weitz J I, Ginsberg J S, Yusuf S. Unfractionated heparin and low-molecular-weight heparin in acute coronary syndrome without ST-elevation: a meta-analysis.  Lancet. 2000;  355 1936-1942
    Google Scholar
  • 16 Fox K A, Goodman S, Bigonzi F, Le Louer V, Cohen M. Inter-regional differences and outcome in unstable angina; analysis of the international ESSENCE trial. Efficacy and Safety of Subcutaneous Enoxaparin in Non-Q-wave Coronary Events.  Eur Heart J. 2000;  21 1433-1439
    Google Scholar
  • 17 FRISC-Study Group. Fragmin during instability in Coronary Artery Disease (FRISC) Study Group . Low-molecular-weight heparin during instability in coronary artery disease.  Lancet. 1996;  347 561-568
    Google Scholar
  • 18 FRISC-II-Study Group . Invasive compared with non-invasive treatment in unstable coronary-artery disease: FRISC II prospective randomised multicentre study.  Lancet. 1999;  354 708-714
    Google Scholar
  • 19 FRISC-II-Study Group . Long-term low-molecular-mass heparin in unstable coronary-artery disease: FRISC II prospective randomised multicentre study.  Lancet. 1999;  354 701-707
    Google Scholar
  • 20 Glick A, Kornowsky R, Michowich Y. et al . Reduction of reinfarction and angina with use of low-molecular-weight heparin therapy after streptokinase (and heparin) in acute myocardial infarction.  Am J Cardiol. 1996;  77 1145-1148
    Google Scholar
  • 21 Goodman S G, Cohen M, Bigonzi F. et al . Randomized trial of low molecular weight heparin (enoxaparin) versus unfractionated heparin for unstable coronary artery disease: one-year results of the ESSENCE Study. Efficacy and Safety of Subcutaneous Enoxaparin in Non-Q Wave Coronary Events.  J Am Coll Cardiol. 2000;  36 693-698
    Google Scholar
  • 22 Goodman S G, Barr A, Sobtchouk A. et al . Low molecular weight heparin decreases rebound ischemia in unstable angina or non-Q-wave myocardial infarction: the Canadian ESSENCE S segment monitoring substudy.  J Am Coll Cardiol. 2000;  36 1507-1513
    Google Scholar
  • 23 Goodman S G, Bozovich G, Tan M. et al . The greatest benefit of enoxaparin (low molecular weight heparin) over unfractionated heparin in acute coronary syndromes is achieved in patients presenting with ST segment depression.  Circulation. 2001;  104 (Suppl II) 549
    Google Scholar
  • 24 Granger C B, Miller J M, Bovill E G. et al . Rebound increase in thrombin generation and activity after cessation of intravenous heparin in patients with acute coronary syndromes.  Circulation. 1995;  91 1929-1935
    Google Scholar
  • 25 Gurfinkel E, Manos E J, Mejail R I. et al . Low molecular weight heparin versus regular heparin or aspirin in the treatment of unstable angina and silent ischemia.  J Am Coll Cardiol. 1995;  26 313-318
    Google Scholar
  • 26 Hamm C W, Braunwald E. A classification of unstable angina revisited.  Circulation. 2000;  102 118-122
    Google Scholar
  • 27 Hamm C W, Bertrand M, Braunwald E. Acute coronary syndrome without ST elevation: implementation of new guidelines.  Lancet. 2001;  358 1533-1538
    Google Scholar
  • 28 Hirsh J, Levine M N. Low molecular weight heparin.  Blood. 1992;  79 1-17
    Google Scholar
  • 29 Hirsh J, Fuster V. Guide to anticoagulant therapy. Part 1: Heparin.  Circulation. 1994;  89 1449-1468
    Google Scholar
  • 30 Joint European Society of Cardiology/American College of Cardiology Committee . Myocardial infarction redefined: a consensus document of the Joint European Society of Cardiology/American College of Cardiology Committee for the redefinition of Myocardial infarction.  Eur Heart J. 2000;  21 1502-1513
    Google Scholar
  • 31 Kaul S, Shah K. Low molecular weight heparin in acute coronary syndrome. Evidence for superior or equivalent efficacy compared with unfractionated heparin?.  J Am Coll Cardiol. 2000;  35 1699-1712
    Google Scholar
  • 32 Kereiakes D J, Grines C, Fry E. et al . Enoxaparin and abciximab adjunctive pharmacotherapy during percutaneous coronary intervention.  J Invasive Cardiol. 2001;  13 272-278
    Google Scholar
  • 33 Kereiakes D J, Kleiman N S, Fry E. et al . Dalteparin in combination with abciximab during percutaneous coronary intervention.  Am Heart J. 2001;  141 348-352
    Google Scholar
  • 34 Klein W, Buchwald A, Hillis S E. et al . Comparison of low-molecular-weight heparin with unfractionated heparin acutely and with placebo for 6 weeks in the management of unstable coronary artery disease: the Fragmin in Unstable Coronary Artery Disease Study (FRIC).  Circulation. 1997;  95 61-68
    Google Scholar
  • 35 Kontny F, Dale J, Abilgaard U. et al . Randomized trial of low-molecular weight heparin (Dalteparin) in prevention of left ventricular thrombus formation and arterial embolism after acute anterior myocardial infarction. The Fragmin in Acute Myocardial Infarction (FRAMI) Study.  J Am Coll Cardiol. 1997;  30 962-969
    Google Scholar
  • 36 Kovar D, Canto J G, Rogers W J. Is low molecular weight heparin in combination with iv lytic therapy safe and effective?.  Circulation. 2001;  104 (Suppl II) 88
    Google Scholar
  • 37 Leizorovicz A. for the FRAX.I.S. Study Group . Comparison of two treatment durations (6 days and 14 days) of a low molecular weight heparin with a 6-day treatment of unfractionated heparin in the initial management of unstable angina or non-Q-wave myocardial infarction: FRAX.I.S. (Fraxiparine in Ischemic Syndrome).  Eur Heart J. 1999;  20 1553-1562
    Google Scholar
  • 38 Levine G N, Ali M N, Schafer A I. Antithrombotic therapy in patients with acute coronary syndromes.  Arch Intern Med. 2001;  161 937-948
    Google Scholar
  • 39 Lindahl B, Venge, P, Wallentin L. for the Fragmin in Unstable Coronary Artery Disease (FRISC) Study Group . Troponin T identifies patients with unstable coronary artery disease who benefit from long-term antithrombotic protection.  J Am Coll Cardiol. 1997;  29 43-48
    Google Scholar
  • 40 Mark D B, Cowper P A, Berkowitz S D. et al . Economic assessment of low-molecular-weight heparin (enoxaparin) versus unfractionated heparin in acute coronary syndrome patients. Results from the ESSENCE randomized trial.  Circulation. 1998;  97 1702-1707
    Google Scholar
  • 41 McLean J. The thromboplastic action of cephalin.  Am J Physiol. 1916;  41 250-257
    Google Scholar
  • 42 Montalesot G, Philippe F, Ankri A. et al. for the French Investigators of the ESSENCE Trial . Early increase of von Willebrand factor predicts adverse outcome in unstable coronary artery disease. Beneficial effects of enoxaparin.  Circulation. 1998;  98 294-299
    Google Scholar
  • 43 O¿Brian B J, Willan A, Blackhouse G, Goeree R, Cohen M, Goodman S. Will the use of low-molecular weight-heparin (enoxaparin) in patients with acute coronary syndrome save costs in Canada?.  Am Heart J. 2000;  139 423-429
    Google Scholar
  • 44 Oler A, Whooley M A, Oler J, Grady D. Adding heparin to aspirin reduces the incidence of myocardial infarction and death in patients with unstable angina: a meta-analysis.  J Am Med Ass. 1996;  276 811-815
    Google Scholar
  • 45 Ross A M, Molhoek P, Lundergan C. et al . Randomized comparison of enoxaparin, a low-molecular-weight heparin, with unfractionated heparin adjunctive to recombinant tissue plasminogen activator thrombolysis and aspirin. Second trial of heparin and aspirin reperfusion therapy (HART II).  Circulation. 2001;  104 648-652
    Google Scholar
  • 46 Theroux P, Waters D D, Lam J, Juneau M, McCans J. Reactivation of unstable angina following discontinuation of heparin.  N Engl J Med. 1992;  327 141-145
    Google Scholar
  • 47 Turpie A GG, Antman E M. Low-molecular-weight heparins in the treatment of acute coronary syndromes.  Arch Intern Med. 2001;  161 1484-1490
    Google Scholar
  • 48 Wallentin L, Lagerqvist B, Husted S. et al . Outcome at 1 year after an invasive compared with a non-invasive strategy in unstable coronary-artery disease: the FRISC II invasive randomised trial.  Lancet. 2000;  356 9-16
    Google Scholar
  • 49 Wallentin L, Dellborg M, Lindahl B, Nilsson T, Pehrsson K, Swahn E. The low-molecular-weight heparin dalteparin as adjuvant therapy in acute myocardial infarction: the ASSENT PLUS study.  Clin Cardiol. 2001;  24 (Suppl I) I12-I14
    Google Scholar
  • 50 Warkentin T E, Levine M N, Hirsh J. et al . Heparin-induced Thrombocytopenia in patients treated with low-molecular-weight heparin or unfractionated heparin.  N Engl J Med. 1995;  332 1330-1335
    Google Scholar

Priv.-Doz. Dr. med. Jörg Carlsson

Medizinische Klinik II
Klinikum Lippe-Detmold GmbH

Röntgenstraße 18

32756 Detmold

Phone: 05231/721185

Fax: 05231/721214

Email: Joerg.Carlsson@Klinikum-Lippe.de

      >